Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Yuping Tongqiao Tablets for persistent allergic rhinitis
ChiCTR2200061367Phase 3Completed
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Yuping Tongqiao Tablet in persistent allergic rhinitis (PAR) (2 arms), sponsored by Beijing Hospital of Traditional Chinese Medicine. Primary endpoint: Total nasal symptom score. Started Apr 2022; status: completed.
02
Drugs
Yuping Tongqiao Tablet
03
Conditions
persistent allergic rhinitis (PAR)
Beyond the preview
Go deeper on ChiCTR2200061367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061367.